Amyloidosis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
==Prognosis== | ==Prognosis== | ||
* In primary (AL) amyloidosis survival rate depends on:<ref name="pmid22909024">{{cite journal |vauthors=Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A |title=Al amyloidosis |journal=Orphanet J Rare Dis |volume=7 |issue= |pages=54 |date=August 2012 |pmid=22909024 |pmc=3495844 |doi=10.1186/1750-1172-7-54 |url=}}</ref> | |||
** The spectrum of organ involvement (amyloid heart disease is the main prognostic factor) | |||
** The severity of organs involvement | |||
** Haematological response to treatment | |||
* The median survival of patients with AL amyloidosis is aproximately 3.8 years.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | * The median survival of patients with AL amyloidosis is aproximately 3.8 years.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | ||
* In AL amyloidosis 27% of patients dying within 1 year from diagnosis. | * In primary (AL) amyloidosis 27% of patients dying within 1 year from diagnosis. | ||
* The major determinant of outcome in amyloidosis is the extent of cardiac involvement. | * The major determinant of outcome in amyloidosis is the extent of cardiac involvement. | ||
** Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%. | ** Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%. | ||
Revision as of 20:28, 8 May 2018
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Amyloidosis natural history, complications and prognosis |
|
FDA on Amyloidosis natural history, complications and prognosis |
|
CDC on Amyloidosis natural history, complications and prognosis |
|
Amyloidosis natural history, complications and prognosis in the news |
|
Blogs on Amyloidosis natural history, complications and prognosis |
|
Risk calculators and risk factors for Amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in body organs, causing organ dysfunction and eventually death.[1]
Complications
Prognosis
- In primary (AL) amyloidosis survival rate depends on:[2]
- The spectrum of organ involvement (amyloid heart disease is the main prognostic factor)
- The severity of organs involvement
- Haematological response to treatment
- The median survival of patients with AL amyloidosis is aproximately 3.8 years.[3]
- In primary (AL) amyloidosis 27% of patients dying within 1 year from diagnosis.
- The major determinant of outcome in amyloidosis is the extent of cardiac involvement.
- Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%.
References
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A (August 2012). "Al amyloidosis". Orphanet J Rare Dis. 7: 54. doi:10.1186/1750-1172-7-54. PMC 3495844. PMID 22909024.
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.